Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg
Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t
The US Veterans Health Administration recently announced that it will cover the cost of Biogen’s lecanemab for veterans suffering from early stages of Alzheimer’s disease.
Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock
Walgreens' move into the clinical trials category has earned it a deal with biotech company Prothena, which will use its network of community pharmacies to identify and re
Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s dise